Laparoscopic radical nephrectomy after shrinkage of a caval tumor thrombus with sunitinib

Nature Reviews Urology

Volumn 6, Issue 6, 2009, Pages 338-343

  Harshman, Lauren C ^a   Srinivas, Sandy ^a   Kamaya, Aya ^b   Chung, Benjamin I ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DENDRITIC CELL VACCINE; GADOLINIUM; LACTATE DEHYDROGENASE; RADIOISOTOPE; SUNITINIB; INDOLE DERIVATIVE; PYRROLE DERIVATIVE;

ABDOMINAL PAIN; ADULT; ANAMNESIS; ARTICLE; BLOOD CELL COUNT; BONE SCINTISCANNING; CANCER GROWTH; CANCER STAGING; CASE REPORT; CAVA VEIN; COMPUTER ASSISTED TOMOGRAPHY; EMERGENCY WARD; ESOPHAGITIS; FATIGUE; FEMALE; FLANK PAIN; HAND FOOT SYNDROME; HUMAN; HYPOTHYROIDISM; KIDNEY CARCINOMA; LACTATE DEHYDROGENASE BLOOD LEVEL; LAPAROSCOPIC SURGERY; LUNG BIOPSY; LUNG METASTASIS; LYMPH NODE METASTASIS; MULTIPLE CYCLE TREATMENT; NEPHRECTOMY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; RADICAL NEPHRECTOMY; TREATMENT RESPONSE; TUMOR THROMBUS; KIDNEY TUMOR; LAPAROSCOPY; METHODOLOGY; MIDDLE AGED; RADIOGRAPHY; THROMBOSIS; VASCULAR TUMOR;

FEMALE; HUMANS; INDOLES; KIDNEY NEOPLASMS; LAPAROSCOPY; MIDDLE AGED; NEPHRECTOMY; PYRROLES; THROMBOSIS; VASCULAR NEOPLASMS;

EID: 70749100131     PISSN: 17594812     EISSN: 17594820     Source Type: Journal    
DOI: 10.1038/nrurol.2009.84     Document Type: Article

References (41)

1. Motzer, R. J. et al. activity of su11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 24, 16-24 (2006).
2. Rini, B. I. tyrosine-kinase inhibitors in a presurgical setting. Presented at the american society of clinical Oncology 2009 Genitourinary cancers symposium, 2009 February 26-28, Orlando, FL, usa.
3. thomas, a. a. et al. Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J. Urol. 181, 518-523 (2009).
4. Wood, c. G. Multimodal approaches in the management of locally advanced and metastatic renal cell carcinoma: combining surgery and systemic therapies to improve patient outcome. Clin. Cancer Res. 13, 697s-702s (2007).
5. escudier, B. et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 27, 1280-1289 (2009).
6. Motzer, R. J. et al. sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 356, 115-124 (2007).
7. Jemal, a. et al. cancer statistics, 2008. CA Cancer J. Clin. 58, 71-96 (2008).
8. Herman, J. G. et al. silencing of the VHL tumorsuppressor gene by dNa methylation in renal carcinoma. Proc. Natl Acad. Sci. USA 91, 9700-9704 (1994).
9. choueiri, t. K. et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J. Urol. 180, 860-865 (2008).
10. Motzer, R. J. et al. survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J. Clin. Oncol. 17, 2530-2540 (1999).
11. Mekhail, t. M. et al. Validation and extension of the Memorial sloan-Kettering prognostic factors model for survival in patients with previously untreated metastatic renal cell carcinoma. J. Clin. Oncol. 23, 832-841 (2005).
12. Motzer, R. J., Bacik, J., Murphy, B. a., Russo, P. & Mazumdar, M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J. Clin. Oncol. 20, 289-296 (2002).
13. choueiri, t. K. et al. clinical factors associated with outcome in patients with metastatic clearcell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy. Cancer 110, 543-550 (2007).
14. Kearney, G. P., Waters, W. B., Klein, L. a., Richie, J. P. & Gittes, R. F. Results of inferior vena cava resection for renal cell carcinoma. J. Urol. 125, 769-773 (1981).
15. Libertino, J. a., Zinman, L. & Watkins, e. Jr. Longterm results of resection of renal cell cancer with extension into inferior vena cava. J. Urol. 137, 21-24 (1987).
16. Neves, R. J. & Zincke, H. surgical treatment of renal cancer with vena cava extension. Br. J. Urol. 59, 390-395 (1987).
17. skinner, d. G., Pritchett, t. R., Lieskovsky, G., Boyd, s. d. & stiles, Q. R. Vena caval involvement by renal cell carcinoma: surgical resection provides meaningful long-term survival. Ann. Surg. 210, 387-392 (1989).
18. yagoda, a., Petrylak, d. & thompson, s. cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. North Am. 20, 303-321 (1993).
19. Fyfe, G. et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 13, 688-696 (1995).
20. Fyfe, G. a. et al. Long-term response data for 255 patients with metastatic renal cell carcinoma treated with high-dose recombinant interleukin-2 therapy. J. Clin. Oncol. 14, 2410-2411 (1996).
21. Mcdermott, d. F. et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 23, 133-141 (2005).
22. escudier, B. et al. sorafenib in advanced clearcell renal-cell carcinoma. N. Engl. J. Med. 356, 125-134 (2007).
23. Figlin, R. a. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRcc). Presented at the american society of clinical Oncology 2008 annual meeting, 2008 May 30-June 3, chicago, IL, usa.
24. Motzer, R. J. et al. sunitinib in patients with metastatic renal cell carcinoma. JAMA 295, 2516-2524 (2006).
25. Flanigan, R. c. et al. cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J. Urol. 171, 1071-1076 (2004).
26. Flanigan, R. c. et al. Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N. Engl. J. Med. 345, 1655-1659 (2001).
27. Mickisch, G. H., Garin, a., van Poppel, H., de Prijck, L. & sylvester, R. Radical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trial. Lancet 358, 966-970 (2001).
28. Walther, M. M. et al. cytoreductive surgery prior to interleukin-2-based therapy in patients with metastatic renal cell carcinoma. Urology 42, 250-257 (1993).
29. Biswas, s., Kelly, J. & eisen, t. cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. Oncologist 14, 52-59 (2009).
30. Rini, B. I. & campbell, s. c. The evolving role of surgery for advanced renal cell carcinoma in the era of molecular targeted therapy. J. Urol. 177, 1978-1984 (2007).
31. escudier, B. et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370, 2103-2111 (2007).
32. Nexavar® (sorafenib) package insert (Bayer Pharmaceuticals, 2007).
33. avastin® (Bevacizumab) package insert (Genentech, 2008).
34. Gordon, M. s. et al. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J. Clin. Oncol. 19, 843-850 (2001).
35. sutent® (sunitinib maleate) package insert (Pfizer, 2007).
36. amin, c. et al. Preoperative tyrosine kinase inhibition as an adjunct to debulking nephrectomy. Urology 72, 864-868 (2008).
37. Margulis, V. et al. surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J. Urol. 180, 94-98 (2008).
38. Neill, M. G., Wei, a. c. & Jewett, M. a. consolidative renal cell carcinoma metastatectomy for partial response after multitargeted tyrosine kinase inhibitor therapy. Urology 70, 178.e9-e11 (2007).
39. scappaticci, F. a. et al. surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab. J. Surg. Oncol. 91, 173-180 (2005).
40. Finelli, a. et al. Laparoscopic cytoreductive nephrectomy for metastatic renal cell carcinoma. BJU Int. 94, 291-294 (2004).
41. Walther, M. M., Lyne, J. c., Libutti, s. K. & Linehan, W. M. Laparoscopic cytoreductive nephrectomy as preparation for administration of systemic interleukin-2 in the treatment of metastatic renal cell carcinoma: a pilot study. Urology 53, 496-501 (1999).